Literature DB >> 27910064

Clinical Behavior and Treatment of Endometrial Cancer.

Divya Gupta1.   

Abstract

Endometrial cancer is the most common gynecologic malignancy diagnosed in women in the developed nations. It affects a disproportionate number of reproductive-aged women. While the overall prognosis is good compared to other cancers affecting women, the pathogenesis and clinical behavior of endometrial cancer are heterogeneous. The risk factors associated with the type I and type II endometrial cancers and their pathogenesis will be discussed, as well as the evaluation and primary treatment of women with endometrial cancer. The chapter will also focus on risk stratification for recurrence after surgery and role of adjuvant treatments. Finally, the treatment of recurrent endometrial cancer will be presented.

Entities:  

Keywords:  Chemotherapy; Endometrial cancer; Fertility sparing; Lymphadenectomy; Lynch syndrome; Minimally invasive surgery; Radiation; Risk factors; Surgery

Mesh:

Year:  2017        PMID: 27910064     DOI: 10.1007/978-3-319-43139-0_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Clinicopathological and prognostic significance of pretreatment thrombocytosis in patients with endometrial cancer: a meta-analysis.

Authors:  Yi-Yang Bai; Lan Du; Li Jing; Tao Tian; Xuan Liang; Min Jiao; Ke-Jun Nan; Hui Guo; Zhi-Ping Ruan
Journal:  Cancer Manag Res       Date:  2019-05-08       Impact factor: 3.989

Review 2.  Epigenetic Dysregulation at the Crossroad of Women's Cancer.

Authors:  Rakesh Kumar; Aswathy Mary Paul; Pranela Rameshwar; M Radhakrishna Pillai
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

3.  Long Noncoding RNA HOXB-AS1 Is Upregulated in Endometrial Carcinoma and Sponged miR-149-3p to Upregulate Wnt10b.

Authors:  Da Liu; Min Qiu; Lili Jiang; Kuiran Liu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 4.  Curcumin anti-tumor effects on endometrial cancer with focus on its molecular targets.

Authors:  Fahime Jahanbakhshi; Parisa Maleki Dana; Bita Badehnoosh; Bahman Yousefi; Mohammad Ali Mansournia; Moghadeseh Jahanshahi; Zatollah Asemi; Jamal Halajzadeh
Journal:  Cancer Cell Int       Date:  2021-02-18       Impact factor: 5.722

5.  Long noncoding RNA SNHG25 promotes the malignancy of endometrial cancer by sponging microRNA-497-5p and increasing FASN expression.

Authors:  Yuhua He; Shuifang Xu; Yi Qi; Jinfang Tian; Fengying Xu
Journal:  J Ovarian Res       Date:  2021-11-18       Impact factor: 4.234

6.  MicroRNA-641 Inhibits Endometrial Cancer Progression via Targeting AP1G1.

Authors:  Yanfen Dong; He Yang; Handan Hua
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-30       Impact factor: 2.650

7.  Predictive factors of surgical site infection after hysterectomy for endometrial carcinoma: a retrospective analysis.

Authors:  Lijuan Shi; Qiao Gu; Fenghua Zhang; Daoyun Li; Wenfeng Ye; Yan Zhong; Xiu Shi
Journal:  BMC Surg       Date:  2021-06-14       Impact factor: 2.102

8.  Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.

Authors:  Jianling Bi; Andreea M Newtson; Yuping Zhang; Eric J Devor; Megan I Samuelson; Kristina W Thiel; Kimberly K Leslie
Journal:  Cancers (Basel)       Date:  2021-06-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.